Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and argenex (NASDAQ:ARGX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Voyager Therapeutics and argenex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -416.32% | -63.42% | -49.40% |
| argenex | 31.66% | 47.70% | 40.12% |
Analyst Recommendations
This is a summary of recent recommendations for Voyager Therapeutics and argenex, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 1 | 0 | 1 | 1 | 2.67 |
| argenex | 0 | 6 | 21 | 1 | 2.82 |
Voyager Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,345.09%. argenex has a consensus target price of $1,155.24, suggesting a potential upside of 20.33%. Given Voyager Therapeutics’ higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than argenex.
Institutional and Insider Ownership
48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Voyager Therapeutics and argenex”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $40.37 million | 2.67 | -$119.72 million | ($1.73) | -1.00 |
| argenex | $4.25 billion | 14.21 | $1.29 billion | $28.66 | 33.50 |
argenex has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Voyager Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, argenex has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Summary
argenex beats Voyager Therapeutics on 10 of the 13 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
About argenex
argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
